Epilepsy in Asia

Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies

“…It is estimated that 23 million people living in Asia have epilepsy 2 . However, epilepsies are associated with high economic, social, and psychological burdens in Asia given that stigma and discrimination against people with epilepsy are common 1,3 . The prevalence and incidence of epilepsy vary between countries.…”

“…There is a lack of epilepsy research in Asia, and efficacy and safety of new antiseizure medications (ASMs), which are the primary treatment option for patients with epilepsy, are often studied in patients from Europe and the United States 3 . However, results of clinical trials in European or North American populations do not always translate to Asian populations 3,6 .…”

“…There is a lack of epilepsy research in Asia, and efficacy and safety of new antiseizure medications (ASMs), which are the primary treatment option for patients with epilepsy, are often studied in patients from Europe and the United States 3 . However, results of clinical trials in European or North American populations do not always translate to Asian populations 3,6 . It is important to consider ethnicity when evaluating ASMs, as patients of different ethnic or racial backgrounds may experience differences in their responses to ASMs due to intrinsic, extrinsic, or genetic factors, which could affect dosing recommendations, efficacy, and safety 6 .…”

“…It is important to consider ethnicity when evaluating ASMs, as patients of different ethnic or racial backgrounds may experience differences in their responses to ASMs due to intrinsic, extrinsic, or genetic factors, which could affect dosing recommendations, efficacy, and safety 6 . Access to ASMs varies across Asia and newer ASMs with more favorable safety profiles may not be available in all countries 3 . Furthermore, licensing of new ASMs in Asia is completed by individual countries and not by a continent‐wide regulatory body 2 .…”

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India

“…Anti‐seizure medications (ASMs) are the primary treatment for epilepsy, yet access varies across Asia; newer ASMs with more favorable safety profiles may not be available in all countries 2 . New ASMs are often studied in select groups of patients in Europe and the USA 2 ; however, results in these populations do not always translate to Asian populations, given differences in genetic backgrounds, 2 which may cause variabilities in drug response and dosing recommendations 6 . Since licensing of new drugs in Asia is by individual countries, 3 it is important to assess ASM efficacy and safety at the individual country level.…”